Liposomal amphotericin B: all 53 studies that test it

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)Not yet recruitingNCT07463040Phase 3
• Liposomal Amphotericin B in Invasive Aspergillosis With Hepatic DysfunctionNot yet recruitingNCT07337720Not applicable
• Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated TalaromycosisNot yet recruitingNCT06926569Not applicable
• Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)Not yet recruitingNCT06525389Phase 3
• Treatment of Mucosal Bolivian LeishmaniasisRecruitingNCT04799236Phase 3
• Chronic Pulmonary Aspergillosis and Ambisome Aerosol with ItraconazoleRecruitingNCT03656081Phase 3
• Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic LeukemiaCompletedNCT01259713Phase 3Results posted
• Antifungal Locks to Treat Fungal-related Central Line InfectionsCompletedNCT00936910Phase 4Results posted
• Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal InfectionsCompletedNCT00418951Phase 2Results posted
• Efficacy and Safety of Topical Amphotericin B Solution in Treatment of Resistant Tinea Capitis in Children 16 Years Old or Less we Follow up Cases Weekly up to 8 Weeks and Notice Improvement of Itching ,Scaling, and Hair Regrowth Then Fungal Culture Done to See if the Solution WorkingActive, not recruitingNCT06980493Phase 2/3
• Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the ElderlyCompletedNCT06449040Phase 1/2
• Bioequivalence of Amphotericin B Liposome for InjectionCompletedNCT05913921Phase 1
• Pharmacokinetics and Safety of AmBisome and DKF-5122CompletedNCT05749380Phase 1
• Olorofim Aspergillus Infection StudyCompletedNCT05101187Phase 3
• A Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy SubjectsCompletedNCT04993222Phase 1
• Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study)CompletedNCT04267497Phase 1
• Short Course Regimens for Treatment of PKDL (Sudan)Status unknownNCT03399955Phase 2
• Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in BangladeshCompletedNCT03311607Phase 4
• Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal MeningitisStatus unknownNCT02686853Phase 4
• Liposomal Amphotericin B (AmBisome) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ASPEN)CompletedNCT02320604Phase 4
• Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).CompletedNCT02273661Phase 2
• Liposomal Amphotericin B for the Treatment of Cryptococcal MeningitisStatus unknownNCT02136030Not applicable
• Liposomal Amphotericin in Disseminated LeishmaniasisCompletedNCT02025491Phase 3
• An Bioequivalence Study to Compare Two 2 mg/ml Liposomal Amphotericin B Injections in Healthy SubjectsCompletedNCT01652859Phase 1
• Single Dose Liposomal Amphotericin B for Visceral LeishmaniasisStatus unknownNCT01566552Phase 4
• SCH708980 With and Without AmBisome for Visceral LeishmaniasisWithdrawnNCT01437020Phase 1/2
• Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in BrazilTerminatedNCT01310738Phase 4
• Safety and Efficacy Study of Inhaled AmBisome for Prevention of Aspergillus Colonization in Lung Transplant RecipientsSuspendedNCT01254708Phase 2
• Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in BangladeshCompletedNCT01122771Phase 3
• Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern AfricaCompletedNCT01067443Phase 2
• Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VLTerminatedNCT00832208Phase 2
• Ambisome® Preemptive Treatment of Multiple Candida Colonization in Sepsis PatientsStatus unknownNCT00697944Phase 4
• Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral LeishmaniasisCompletedNCT00696969Phase 3
• CRITIC - Treatment of Candidemia and Invasive CandidiasisCompletedNCT00670657Phase 4
• Single Infusion of Liposomal Amphotericin B in Indian Visceral LeishmaniasisCompletedNCT00628719Phase 3
• Combination Therapy in Indian Visceral LeishmaniasisCompletedNCT00523965Phase 3
• Pilot Study of High Dose Liposomal Amphotericin B Efficacy in Initial Zygomycosis TreatmentCompletedNCT00467883Phase 2
• Intermittent Liposomal Amphotericin B Primary ProphylaxisStatus unknownNCT00451711Phase 2
• Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to AntibioticsTerminatedNCT00421187Phase 4
• ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic LeukemiaTerminatedNCT00386997Phase 4
• Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azarCompletedNCT00371995Phase 2
• Combination Chemotherapy for the Treatment of Indian Kala-AzarCompletedNCT00370825Phase 2
• PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute LeukaemiaCompletedNCT00362544Phase 4
• COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive AspergillosisCompletedNCT00334412Phase 4
• PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell TransplantationCompletedNCT00326157Phase 2
• Inhalation of Liposomal Amphotericin B to Prevent Invasive AspergillosisCompletedNCT00263315Phase 2/3
• Ambisome in Liver Transplant PatientsTerminatedNCT00161356Phase 4
• Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial TreatmentCompletedNCT00158730Phase 3
• A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell TransplantationCompletedNCT00148148Phase 2
• Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for AspergillosisTerminatedNCT00047827Phase 2
• Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer PatientsCompletedNCT00003938Phase 3
• Liposomal Amphotericin B With or Without Sargramostim in Treating Patients With Invasive Fungal InfectionCompletedNCT00003315Phase 3
• Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver TransplantsCompletedNCT00001107Phase 4

← Liposomal amphotericin B overview